high triglycerides and semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study Semaglutide reduces major adverse CV

This is a large, carefully designed observational study not a randomised trial so it points to a promising signal rather than a proven benefit

Basic criteria to qualify for semaglutide includes a body mass index (BMI) of 27 with at least one health-related condition, or a BMI of 30 or higher

Clinical trials of Zepbound showed it to be more effective than Ozempic for weight-loss (typically 18% of body weight)

Insugen-N 100IU/ml Injection is used to improve blood sugar control in adults and children with type 1 and type 2 diabetes mellitus

This article has explored the scientific rationale, safety considerations, and patient experiences associated with their concurrent use